Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53

Abstract

The anti-cancer agent paclitaxel (Taxol) stabilizes microtubules leading to G2/M cell cycle arrest and apoptotic cell death. In order to analyse the molecular mechanisms of Taxol-induced cytotoxicity, we studied the involvement of mitogen-activated protein kinases (MAPK) ERK and p38 as well as the p53 pathways in Taxol-induced apoptosis. The human breast carcinoma cell line MCF7 and its derivatives, MCF7/HER-2 and MDD2, were used in the study. We found that Taxol treatment strongly activated ERK, p38 MAP kinase and p53 in MAP kinase MCF7 cells prior to apoptosis. PD98059 or SB203580, specific inhibitors of ERK and p38 kinase activities, significantly decreased apoptosis, leaving the surviving cells arrested in G2/M. These inhibitors did not significantly affect Taxol-induced alterations in the cell cycle regulatory proteins Rb, p53, p21/Waf1 and Cdk-2. In addition, inactivation of p53 did not affect cellular sensitivity to Taxol killing. However, cells with inactivated p53, unlike cells harboring wild type p53, failed to arrest in G2/M after treatment with Taxol and continued to divide or go into apoptosis. Our data show that both ERK and p38 MAP kinase cascades are essential for apoptotic response to Taxol-induced cellular killing and are independent of p53 activity. However, p53 may serve as a survival factor in breast carcinoma cells treated with Taxol by blocking cells in G2/M phase of the cell cycle.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE and Nikiforov M. . 1996 Oncogene 12: 2535–2547.

  • Blagosklonny MV, Bishop PC, Robey R, Fojo T and Bates SE. . 2000 Cancer Res. 60: 3423–3428.

  • Blagosklonny MV, Schulte T, Nguyen P, Trepel J and Neckers LM. . 1996 Cancer Res. 56: 1851–1854.

  • Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J and Neckers L. . 1995 Cancer Res. 55: 4623–4626.

  • Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B. . 1998 Science 282: 1497–1500.

  • Campbell JS, Seger R, Graves JD, Graves LM, Jensen AM and Krebs EG. . 1995 Rec. Prog. Horm. Res. 50: 131–159.

  • Carter S, Auer KL, Reardon DB, Birrer M, Fisher PB, Valerie K, Schmidt-Ullrich R, Mikkelsen R and Dent P. . 1998 Oncogene 16: 2787–2796.

  • Chang B-D, Xuan Y, Broude EV, Zhu H, Schott B, Fang J and Roninson IB. . 1999 Oncogene 18: 4808–4818.

  • Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG and Hynes NE. . (1997) Cancer Res. 57: 3804–3811.

  • Daly JM, Monilola AO, Wong AM-L, Neve R, Lane HA, Maurer FG and Hynes NE. . 1999 Oncogene 18: 3440–3451.

  • Dolbeare F, Gratzner H, Pallavicini MG and Gray JW. . 1983 Proc. Natl. Acad. Sci. USA 80: 5573–5577.

  • Erhardt J and Pittman R. . 1998 Oncogene 16: 443–451.

  • Fang M, Liu B, Schmidt M, Lu Y, Mendelsohn J and Fan Z. . 2000 Anticancer Res. 20: 103–112.

  • Goldspiel BR. . (1997) Pharmacotherapy. 17: 110S–125S.

  • Guadagno TM and Ferrell JE. . 1998 Science 282: 1312–1315.

  • Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN. . 1991 J. Natl. Cancer Inst. 83: 1797–1805.

  • Horiuchi M, Hayashida W, Kambe T, Yamada T and Dzau VJ. . 1997 J. Biol. Chem. 272: 19022–19026.

  • Huang Y, Sheikh MS, Fornace Jr AJ and Holbrook NJ. . 1999 Oncogene 18: 3431–3439.

  • Jaaro H, Rubinfeld H, Hanoch T and Seger R. . 1997 Proc. Natl. Acad. Sci. USA 94: 3742–3747.

  • Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbasuer-Wadl H, Mittlbock M, Gnant M, Steger G and Jakesz R. . 2000 Clin. Cancer Res. 6: 50–56.

  • Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus PD, Ratzkin BJ, Seger R, Hynes NE and Yarden Y. . 1996 EMBO J. 15: 254–264.

  • Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ and Pardee AB. . 1994 Cancer Res. 54: 380–385.

  • Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV and Gudkov AV. . 1999 Science 285: 1733–1737.

  • Kottke TJ, Blajeski AL, Martins M, Menser Jr PW, Davidson NE, Earnshaw WC, Armstrong DK and Kaufmann SH. . 1999 J. Biol. Chem. 274: 15927–15936.

  • Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL and Young PR. . 1994 Nature 372: 739–746.

  • Lieu CH, Liu CC, Yu TH, Chen KD, Chang YN and Lai YK. . 1998 Cell Growth Diff. 9: 767–776.

  • McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK and Donehower RC. . 1989 Ann. Intern. Med. 111: 273–279.

  • Mitchell FM, Heasley LE, Qian NX, Zamarripa J and Johnson GL. . 1995 J. Biol. Chem. 270: 8623–8628.

  • Pegram MD, Finn RS, Arzoo K, Beryl M, Pietras RJ and Slamon D. . 1997 Oncogene 15: 537–547.

  • Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D and Yarden Y. . 1993 EMBO J. 12: 961–971.

  • Rasouli-Nia A, Liu D, Perdue S and Britten RA. . 1998 Clin. Cancer Res. 4: 1111–1116.

  • Reszka AA, Seger CD, Dilt EG, Krebs EG and Fischer EH. . 1995 Proc. Natl. Acad. Sci. USA 92: 8881.

  • Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD and Pistenpol JA. . (1998) J. Biol. Chem. 273: 30777–30784.

  • Schiff PB, Fant J and Horwitz SB. . 1979 Nature 277: 665–667.

  • Schmidt M, Lu Y, Liu B, Fang M, Mendelsohn J and Fan Z. . 2000 Oncogene 19: 2423–2429.

  • Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR and Saltiel AR. . 1999 Nat. Med. 5: 810–816.

  • Seger R and Krebs EG. . 1995 FASEB J. 9: 726–735.

  • Shaulian E, Zauberman A, Ginsberg D and Oren M. . 1992 Mol. Cell Biol. 12: 5581–5592.

  • Shepherd PR, Withers DJ and Siddle K. . 1998 Biochem. J. 333: 471–490.

  • Shtil AA, Mandlekar S, Yu R, Walter RJ, Hagen K, Tan T-H, Roninson IB and Kong A-NT. . 1999 Oncogene 18: 377–384.

  • Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS and Longo DL. . 1998 Mol. Cell Biol. 18: 3509–3517.

  • Suzuki A, Tsutomi Y, Akahane K, Araki T and Miura M. . 1998 Oncogene 17: 931–939.

  • Takenaka K, Moriguchi T and Nishida E. . 1998 Science 280: 599–602.

  • Torres K and Horwitz SB. . 1998 Cancer Res. 58: 3620–3626.

  • Turner PF and Margolis RL. . 1984 J. Cell Biol. 99: 940–946.

  • Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW and Galloway DA. . 1996 Nat. Med. 2: 72–79.

  • Waldman T, Lengauer C, Kinzler KW and Bogelstein B. . 1996 Nature 381: 713–716.

  • Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T and Wimalasena J. . 1998 J. Biol. Chem. 273: 4928–4936.

  • Wang T-H, Wang H-S and Soong Y-K. . 2000a Cancer 88: 2619–2628.

  • Wang Y, Blandino G and Givol D. . 1999 Oncogene 18: 2643–2649.

  • Wang X, Martindale JL and Holbrook NJ. . 2000b J. Biol. Chem. 10: 1074.

  • Weinstein E, Grimm S and Leder P. . 1998 Oncogene 17: 2107–2113.

  • Wen D, Suggs SV, Karunagaran D, Liu N, Cupples RL, Luo Y, Janssen AM, Ben-Baruch N, Trollinger DB and Jacobsen VL. . 1994 Mol. Cell Biol. 14: 1909–1919.

  • Widmann C, Johnson NL, Gardner AM, Smith RJ and Johnson GL. . 1997 Oncogene 15: 2439–2447.

  • Wolfson M, Yang CP and Horwitz SB. . 1997 Intl. J. Cancer 70: 248–252.

  • Woods, CM, Zhu J, McQueney PA, Bollag D and Lazarides E. . 1995 Mol. Med. 1: 506–526.

  • Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD and Panayotou G. . 1996 Mol. Cell Biol. 16: 1722–1733.

  • Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME. . 1995 Science 270: 1326–1331.

  • Yu D, Liu B, Tan M, Li J, Wang SS and Hung MC. . 1996 Oncogene 13: 1359–1365.

  • Yung Y, Dolginov Y, Yao Z, Rubinfeld H, Michael D, Hanoch T, Roubini E, Lando Z, Zharhary D and Seger R. . 1997 FEBS Lett. 408: 292–296.

Download references

Acknowledgements

This work was supported by grants from the National Institutes of Health CA60730 and CA75179 to AV Gudkov.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bacus, S., Gudkov, A., Lowe, M. et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20, 147–155 (2001). https://doi.org/10.1038/sj.onc.1204062

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204062

Keywords

This article is cited by

Search

Quick links